Financial Performance - MannKind Corporation reported a record revenue quarter of $82 million[13] - Tyvaso DPI-related revenue reached $59 million in Q3 2025, a 15% increase from Q3 2024[13, 22] - Afrezza net revenue for Q3 2025 was $18.5 million, up 23% from Q3 2024[32] - FUROSCIX net revenue for Q3 2025 was $19.3 million, a 93% increase from Q3 2024[37] - Total revenue increased by 17% from Q3 2024 to Q3 2025[50] Product & Clinical Development - Afrezza sBLA was accepted for review, potentially becoming the first new insulin for pediatrics in over 100 years[13, 62] - FUROSCIX doses dispensed in Q3 2025 increased by 153% from Q3 2024[34] - The ICoN-1 global Phase 3 study achieved its interim enrollment target ahead of schedule[69] - INFLO Nintedanib DPI Phase 2 study was initiated, with the first patient expected to enroll in Q1 2026[15, 77] Market Opportunity - The addressable opportunity for heart failure (HF) is greater than $10 billion[39]

Core Insights - scPharmaceuticals Inc. reported a net revenue of $11.8 million for FUROSCIX in Q1 2025, marking a 93% increase from $6.1 million in Q1 2024 [5] - The company launched FUROSCIX for the treatment of Chronic Kidney Disease (CKD) in April 2025, expanding its market reach [1][2] - The company is on track to submit a supplemental New Drug Application (sNDA) for an autoinjector designed to reduce treatment time significantly by Q3 2025 [1][5] Financial Performance - Product revenues for Q1 2025 were $11.8 million, up from $6.1 million in Q1 2024, reflecting a 93% annual growth [5] - Costs of product revenues increased to $3.5 million in Q1 2025 from $1.8 million in Q1 2024, attributed to higher demand and manufacturing costs [4] - The company reported a net loss of $19.7 million for Q1 2025, compared to a net loss of $14.1 million in Q1 2024 [8] Market and Sales Update - Approximately 13,900 FUROSCIX doses were filled in Q1 2025, representing a 73% increase from about 8,000 doses in Q1 2024 [5] - Sales to Integrated Delivery Networks increased by 119% in Q1 2025 compared to Q4 2024 [5] - The company has seen an increase in Medicare-covered patients, which historically correlates with a rise in FUROSCIX prescription volumes [2] Research and Development - Research and development expenses rose to $4.6 million in Q1 2025 from $2.7 million in Q1 2024, primarily due to increased pharmaceutical development and employee-related costs [6] - Selling, general, and administrative expenses increased to $21.4 million in Q1 2025 from $17.4 million in Q1 2024, driven by higher employee-related costs and commercial expenses [7] Cash Position - As of March 31, 2025, the company had cash and cash equivalents of $57.5 million, down from $75.7 million at the end of 2024 [22]